Kisunla (Donanemab)

Donanemab is a medicine for people in the early stages of Alzheimer's disease. It is given as an infusion into a vein, usually once a month. It works by helping the body clear sticky protein clumps called amyloid plaques from the brain.

Brand names:Kisunla
Medication

What people taking Kisunla (Donanemab) report

Every report comes from a Lived member, sent anonymously.

Have you tried Kisunla (Donanemab) for Alzheimer's?

NameHow it went

About Kisunla (Donanemab)

What It's For

Donanemab, sold as Kisunla, is a prescription treatment for Alzheimer's disease in its early stages. It is meant for people with mild cognitive impairment (memory or thinking problems that are noticeable but still allow largely independent daily life) or mild dementia caused by Alzheimer's. It was not studied in moderate or severe dementia, and it is not started at those stages. Before treatment, the care team must confirm that amyloid, the protein that builds up in the brain in Alzheimer's, is actually present. This is done with an amyloid PET (positron emission tomography) scan or a spinal fluid test, because memory problems can have other causes that this medicine would not help. Kisunla can be used alongside older Alzheimer's medicines that ease symptoms, such as donepezil (Aricept) or memantine (Namenda).

How It Works

In Alzheimer's disease, a protein called amyloid beta clumps together into plaques between brain cells. These plaques are one of the defining features of the disease and are thought to contribute to the damage that slowly erodes memory and thinking. Donanemab is a monoclonal antibody, a laboratory-made immune protein designed to latch onto one specific target. It binds to a form of amyloid found in established plaques and marks it for removal by the brain's immune cells. On PET scans, plaque levels fall steadily over the first year or so of treatment. Clearing plaque does not repair brain cells that have already been lost, which is why the goal is to slow further decline rather than restore earlier abilities.

Dosage & Administration

Kisunla is given as an intravenous infusion (through a drip into a vein) at an infusion center, once every four weeks. Each infusion takes about 30 minutes, followed by at least 30 minutes of observation for reactions. The dose starts low and steps up over the first three infusions before reaching the full maintenance dose from the fourth infusion on. This gradual start is the current recommended schedule because it led to less brain swelling than the original trial schedule. Brain MRI (magnetic resonance imaging) scans are a built-in part of treatment. A recent baseline MRI is needed before the first infusion, then further scans before the second, third, fourth and seventh infusions to look for side effects that usually cause no symptoms. If an infusion is missed, it is given as soon as possible at the same dose, and the four-week schedule resumes from there.

Side Effects

The most important side effect is ARIA (amyloid related imaging abnormalities). It shows up on MRI as temporary swelling in areas of the brain (ARIA-E) or as tiny spots of bleeding or iron deposits on or in the brain (ARIA-H). ARIA is common: in a study of the current dosing schedule, nearly three in ten people had it on a scan within a year. Most never notice it, and it usually appears within the first six months. About 3% had symptoms, and serious cases, including seizures and larger brain bleeds, have occurred and have occasionally been fatal. This is the drug's boxed warning, the most prominent type of warning from the FDA (Food and Drug Administration). New headache, confusion, dizziness, vision changes, nausea or trouble walking during treatment should be reported to the care team right away, since an MRI may be needed. Sudden weakness or numbness on one side, trouble speaking, or a seizure needs a call to 911. Infusion reactions, such as chills, flushing, nausea, sweating, headache, chest discomfort, shortness of breath or blood pressure changes, affected about one in six people on the current schedule, mostly during the first four infusions. They can begin hours after leaving the infusion center; contact the care team right away if they do, and get emergency help for swelling of the face or throat or trouble breathing. Headache is also common on its own.

Interactions & Warnings

Because ARIA and brain bleeding are the main dangers, the biggest decisions are about who faces higher risk. People who carry two copies of the ApoE4 gene variant (about 15% of people with Alzheimer's) have more frequent and more serious ARIA. Genetic testing for ApoE4 is recommended before starting, after a conversation about what the result could mean for the person and their relatives. Earlier MRI findings such as several small bleeds or signs of amyloid in blood vessel walls also raise risk and may rule treatment out. Blood thinners (anticoagulants such as warfarin, apixaban or rivaroxaban) may add to the risk of bleeding in the brain, and expert recommendations advise against Kisunla for people who take them. A blood thinner that is medically needed should not be stopped just to start Kisunla. Aspirin was commonly used in the trials. ARIA can look like a stroke, and clot-busting stroke drugs can cause dangerous bleeding in someone taking Kisunla. Carry a wallet card or other note saying you receive Kisunla, so emergency teams know before choosing a treatment. A previous serious allergic reaction to donanemab rules out further doses. There is no information on use during pregnancy or breastfeeding.

What to Expect

Treatment is a significant routine: monthly infusion visits, several MRI scans in the first year, and closer attention to new symptoms during the first six months, when ARIA is most likely. If ARIA appears on a scan, infusions may be paused until it settles, and most cases resolve within a few months. The benefit is a slower decline, not a halt or a reversal. In the main trial, people on donanemab declined about 29% less than those on placebo over 76 weeks on a standard rating of memory, thinking and daily function. People and families are unlikely to see improvement; the hope is that abilities hold up somewhat longer than they otherwise would. Unlike some ongoing treatments, Kisunla can be stopped once a follow-up amyloid PET scan, often done 12 to 18 months in, shows that plaques have been cleared to minimal levels. In the trial, about half of people reached that point by one year. Amyloid slowly builds up again afterward, and there is not yet evidence on whether later doses are needed.

Questions to Ask Your Doctor

  1. 1.Based on my tests, how much benefit could I realistically expect, and how would we judge whether it is worth continuing?
  2. 2.Should I have ApoE4 genetic testing, and how would the result change my risk or our decision?
  3. 3.Do my current medicines, especially any blood thinner, or my MRI findings make Kisunla riskier for me?
  4. 4.Which symptoms between infusions should make me call you, and who do I contact after hours?
  5. 5.When would we check whether the amyloid has cleared, and what happens if I stop treatment?

Last reviewed • Oct 2026

Educational content, not medical advice.